An important regulatory submission from Eli Lilly (NYSE: LLY) has not been successful, with the US regulator issuing a complete response letter (CRL) for mirikizumab in ulcerative colitis.
The rebuff will set back the timeline for approval, with questions being raised in relation to the proposed manufacturing process.
The US Food and Drug Administration did not raise any concerns regarding the data package or safety of the medicine, Lilly said in a statement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze